Aicardi-Goutières Syndrome (AGS) Natural History Research
![Doctor in lab](https://www.chop.edu/sites/default/files/styles/teaser/public/16CHOP0137-canonical-general-780x439-43.jpg?itok=VO78H0Or)
This study gathers natural history information about your child’s Aicardi-Goutières syndrome disease progression. A visit to CHOP is not required.
This study gathers natural history information about your child’s Aicardi-Goutières syndrome disease progression. A visit to CHOP is not required.
Individuals with a confirmed diagnosis of Aicardi-Goutières syndrome (AGS) may qualify to participate in a Phase II clinical trial investigating the safety and efficacy of a Janus kinase (JAK) inhibitor known as baricitinib.
Individuals with a suspected diagnosis of leukodystrophy may be eligible to participate in a research study investigating the efficacy of whole genome sequencing as a first-line diagnostic tool.
The Myelin Disorders Biorepository Project (MDBP) collects and analyzes clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future scientific research.